Screener
Tango Therapeutics TNGX Personnel-Related Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Oncology Segment / Three Months Ended March 31, 2026 | Oncology Segment / Three Months Ended March 31, 2025 |
|---|---|---|
| TNG260 direct program expenses - R&D | 2,009 | 1,730 |
| TNG961 direct program expenses - R&D | 408 | 2,221 |
| TNG908 direct program expenses* - R&D | 581 | 1,712 |
| Discovery direct program expenses - R&D | 1,872 | 4,679 |
| Personnel-related expenses - R&D | 12,931 | 13,850 |
| Facilities and other related expenses - R&D | 4,338 | 5,465 |
| Other segment expenses (a) | 11,980 | 8,826 |
| Segment net loss | $(45,514) | $(39,876) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's personnel-related expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported personnel-related expenses-rd — research and development expense of $12.93M in Q1 2026.
- How has Tango Therapeutics's personnel-related expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's personnel-related expenses-rd — research and development expense decreased by 6.6% year-over-year, from $13.85M to $12.93M.
- What is the long-term trend for Tango Therapeutics's personnel-related expenses-rd — research and development expense?
- Over 3 years (2022 to 2025), Tango Therapeutics's personnel-related expenses-rd — research and development expense has grown at a 22.2% compound annual growth rate (CAGR), from $28.19M to $51.47M.
- What does personnel-related expenses-rd — research and development expense mean?
- This metric represents the total compensation and benefits costs allocated specifically to the research and development function within the organization. It captures the investment in human capital required to drive drug discovery, clinical trial execution, and scientific innovation. Monitoring this figure provides insight into the company's commitment to internal talent development and the operational intensity of its pipeline advancement efforts.
Ask your AI about Tango Therapeutics's personnel-related expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude